Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysisCaroline Mollévi, Thierry Conroy, Sophie Gourgou et al.|European Journal of Cancer|2023Cited by 37
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancerCaroline Mollévi, Thierry Conroy, Sophie Gourgou et al.|European Journal of Cancer|2017Cited by 22
Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of resultsCaroline Mollévi, Amélie Anota, Antoine Barbieri et al.|Quality of Life Research|2020Cited by 18
When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trialsCélia Touraine, Caroline Mollévi, Benjamin Cuer et al.|BMC Medical Research Methodology|2023Cited by 16
Impact of single‐nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD‐12/PRODIGE‐2 phase III trialValérie Boige, Pierre Laurent‐Puig, Jean‐Pierre Gerard et al.|International Journal of Cancer|2019Cited by 11